Date: October 12, 2023
Time: 8:00am PDT, 10:00am CDT, 11:00am EDT, 5:00pm CEST
Patient-derived tumoroids, commonly referred to as cancer organoids, represent a promising avenue as cost-effective and biologically relevant cancer immunotherapy research models. In this study, we developed a proof-of-concept immunotherapy screening platform harnessing tumoroids to validate the cytotoxic activity of Natural Killer (NK) cells. Tumoroids were genetically engineered to create a GFP-expressing reporter pool that could be used to assess killing efficiency using live cell imaging platforms. We were able to demonstrate dose-dependent tumoroid killing with increasing effector-to-target ratios. This innovative approach holds the potential to streamline the engineering of patient-derived tumoroid models, facilitate the development of multiplex-killing assays, and provide an efficient tool for evaluating immunotherapies targeting solid tumors.
- Explore the applications of tumoroids in cancer immunotherapy workflows
- Establish and engineer patient-derived reporter tumoroid models
- Develop and optimize assays for immunotherapy screens using tumoroid co-cultures
Webinars will be available for unlimited on-demand viewing after live event.